Story
Silence Therapeutics Stock Slides on Discounted $175 Million Share Offering

Shares of Silence Therapeutics (NASDAQ: SLN) fell in pre-market trading after the biotechnology company priced a significant underwritten public offering at a discount to its recent market value. The move is intended to raise approximately $175 million in gross proceeds, but the pricing has created near-term pressure on the stock.
Details of the Offering
The company announced it is offering approximately 12.96 million American Depositary Shares (ADSs) to the public at a price of $13.50 per share. This price represents a notable discount from where the stock had been trading prior to the announcement.
Underwriters have a 30-day option to purchase up to an additional 1.94 million ADSs, which could increase the total capital raised but would also result in further shareholder dilution. Such offerings, while common for development-stage biotech firms needing capital, often cause a stock's price to fall toward the offering price as existing shares are devalued.
Context of Positive Clinical News
The capital raise comes just days after Silence Therapeutics reported a significant clinical milestone. On August 10, the company disclosed positive topline results from its Phase 2 SANRECO trial for divesiran, a first-in-class siRNA therapy for the blood disorder polycythemia vera.
AdPartially buffering the negative sentiment from the offering, Morgan Stanley maintained its Overweight rating on the stock and raised its price target to $32 from $25. This indicates underlying confidence from analysts in the company's long-term prospects, though it was not enough to prevent the stock's immediate slide.
Market Reaction
In pre-open trading, Silence Therapeutics stock slipped 1.8%, a move attributed directly to the offering's dilutive effect. The decline occurred while the broader U.S. market showed strength, with major indices like the NASDAQ and S&P 500 trading higher, confirming that the sell-off was company-specific.
For investors, the discounted offering has overshadowed the positive clinical trial data and bullish analyst outlook in the short term. The immediate reality of dilution is anchoring the stock's price, demonstrating a classic tension between a company's long-term potential and its near-term financing needs.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.